ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1512-1519

  Jia, Hong Yun ^a   Wu, Jiang Xue ^a   Zhu, Xiao Feng ^a   Chen, Jie Min ^a   Yang, Shi Ping ^a   Yan, Hai Jiao ^a   Tan, Li ^a   Zeng, Yi Xin ^a   Huang, Wenlin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Bax; Bcl 2; Imatinib resistant; Src; STAT3

Indexed keywords

CYCLINE; IMATINIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; K562 CELLS; PIPERAZINES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; SRC-FAMILY KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 68649114076     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.033     Document Type: Article

References (56)

1. Goldman J.M., and Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349 (2003) 1451-1464
2. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
3. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002) 3530-3539
4. Kantarjian H.M., Cortes J., O'Brien S., Giles F.J., Albitar M., Rios M.B., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99 (2002) 3547-3553
5. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
6. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
7. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
8. von Bubnoff N., Schneller F., Peschel C., and Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359 (2002) 487-491
9. White D.L., Saunders V.A., Dang P., Engler J., Zannettino A.C., Cambareri A.C., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
10. Gambacorti-Passerini C., Barni R., le Coutre P., Zucchetti M., Cabrita G., Cleris L., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92 (2000) 1641-1650
11. Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., and Hallek M. Activation of Src kinases p53/56Lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 56 (1996) 3589-3596
12. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., and Griffin J.D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7 (2007) 345-356
13. Kotaki M., Motoji T., Takanashi M., Wang Y.H., and Mizoguchi H. Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. Cancer Lett 199 (2003) 61-68
14. Meyn III M.A., Wilson M.B., Abdi F.A., Fahey N., Schiavone A.P., Wu J., et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 281 (2006) 30907-30916
15. Wu J., Meng F., Kong L.-Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 100 (2008) 927-940
16. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49 January (1) (2008) 19-26
17. Dai Y., Rahmani M., Pei X.Y., Dent P., and Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 104 (2004) 509-518
18. Ptasznik A., Nakata Y., Kalota A., Emerson S.G., and Gewirtz A.M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL(+) leukemia cells. Nat Med 10 (2004) 1187-1189
19. Johnson F.M., Saigal B., Tran H., and Donato N.J. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 13 (2007) 4233-4244
20. Cirinnà M., Trotta R., Salomoni P., Kossev P., Wasik M., Perrotti D., et al. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood 96 (2000) 3915-3921
21. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103 40 (2006 Oct 3) 14907-14912
22. Kline M.P., Rajkumar S.V., Timm M.M., Kimlinger T.K., Haug J.L., Lust J.A., et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21 (2007) 1549-1560
23. Kuroda J., Kimura S., Strasser A., Andreeff M., O'Reilly L.A., Ashihara E., et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 14 (2007) 1667-1677
24. Salomoni P., Condorelli F., Sweeney S.M., and Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 96 (2000) 676-684
25. 2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL. J Pharmacol Exp Ther 310 (2004) 1084-1095
26. Tauchi T., Sumi M., Nakajima A., Sashida G., Shimamoto T., and Ohyashiki K. Bcl-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 9 (2003) 4267-4273
27. Kantarjian H.M., Giles F., Quintás-Cardama A., and Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13 (2007) 1089-1097
28. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 (2002) 4645-4655
29. Conrad C., Ischenko I., Köhl G., Wiegand U., Guba M., Yezhelyev M., et al. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 18 (2007) 569-579
30. Choi S., Sano D., Cheung M., Zhao M., Jasser S.A., Ryan A.J., et al. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 14 (2008) 5081-5089
31. Sasaki T., Tanno S., Shibukawa K., Osanai S., Kawabe J., and Ohsaki Y. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. Int J Oncol 33 (2008) 525-532
32. Alferez D., Wilkinson R.W., Watkins J., Poulsom R., Mandir N., Wedge S.R., et al. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. Mol Cancer Ther 7 (2008) 590-598
33. Heymach J.V., Paz-Ares L., De Braud F., Sebastian M., Stewart D.J., Eberhardt W.E., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26 (2008) 5407-5415
34. Natale R.B. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 3 (2008) S128-S130
35. Lee C.B., and Socinski M.A. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Rev Recent Clin Trials 2 (2007) 117-120
36. Kiura K., Nakagawa K., Shinkai T., Eguchi K., Ohe Y., Yamamoto N., et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3 (2008) 386-393
37. Nishioka C., Ikezoe T., Takeshita A., Yang J., Tasaka T., Yang Y., et al. ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244. Leukemia 21 (2007) 1308-1310
38. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
39. Xiao X., Wu J., Zhu X., Zhao P., Zhou J., Liu Q.Q., et al. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 121 (2007) 2095-2104
40. Wu J., Xiao X., Zhao P., Xue G., Zhu Y., Zhu X., et al. Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 12 (2006) 4702-4713
41. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
42. Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111 (2008) 3821-3829
43. Dai Y., Rahmani M., Corey S.J., Dent P., and Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279 (2004) 34227-34239
44. Ruvolo P.P., Deng X., and May W.S. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15 (2001) 515-522
45. Gustafson D.L., Bradshaw-Pierce E.L., Merz A.L., and Zirrolli J.A. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther 318 (2006) 872-880
46. Arao T., Yanagihara K., Takigahira M., Takeda M., Koizumi F., Shiratori Y., et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 118 (2006) 483-489
47. Deguchi Y., Kimura S., Ashihara E., Niwa T., Hodohara K., Fujiyama Y., et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32 (2008) 980-983
48. Cortes J., Kim D.W., Raffoux E., Martinelli G., Ritchie E., Roy L., et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22 (2008) 2176-2183
49. Nimmanapalli R., O'Bryan E., Huang M., Bali P., Burnette P.K., Loughran T., et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Ablpositive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 62 (2002) 5761-5769
50. Huang X.F., Luo S.K., Xu J., Li J., Xu D.R., Wang L.H., et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 111 5 (2008) 2854-2865
51. Yamanaka K., Rocchi P., Miyake H., Fazli L., Vessella B., Zangemeister-Wittke U., et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4 (2005) 1689-1698
52. Sinicrope F.A., and Penington R.C. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 4 (2005) 1475-1483
53. Arunasree K.M., Roy K.R., Anilkumar K., Aparna A., Reddy G.V., and Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res 32 (2008) 855-864
54. Coppo P., Dusanter-Fourt I., Millot G., Nogueira M.M., Dugray A., Bonnet M.L., et al. Constitutive and specific activation of STAT3 by BCRABL in embryonic stem cells. Oncogene 22 (2003) 4102-4110
55. Mow B.M., Chandra J., Svingen P.A., Hallgren C.G., Weisberg E., Kottke T.J., et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99 (2002) 664-671
56. Veldurthy A., Patz M., Hagist S., Pallasch C.P., Wendtner C.M., Hallek M., et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 112 (2008) 1443-1452